A possible explanation for the therapeutic failure of CTLA-4, PD-1 or PD-L1 blockade therapy in PDA is the lack of a nature infiltration of effector immune cells in the majority of PDA. The gene discussed is CD274; the disease is Patent ductus arteriosus.